Skip to main content
CDC Website

TB

Latent TB Infection Risk Assessment Tool

This tool is designed to assist health care workers prioritize asymptomatic adults for latent TB infection (LTBI) testing.

Generic Programmatic and Clinical Guide for the Introduction of new drugs and Shorter Regimens for the Treatment of Multi/Extensively Drug-Resistant Tuberculosis

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

What You Need to Know About Your Medicine for Latent Tuberculosis (TB) Infection – Isoniazid and Rifapentine

This Latent TB Infection (LTBI) Treatment Fact Sheet Series is designed to complement patient education delivered by healthcare professionals. Each sheet provides patients with a written reminder of their treatment regimen, medication side effects, actions to take if side effects do occur, tips to help remain adherent to the medication, and instructions in the event a dose of medication is missed.

MMWR: Exposure of Passengers and Flight Crew to Mycobacterium Tuberculosis on Commercial Aircraft, 1992-1995.

This report summarizes CDC and State health departments investigations and provides guidance about notification of passengers and flight crew after exposure to TB during travel on commercial aircrafts. From January 1993 through February 1995, CDC and State health departments completed an investigation of six instances in which passengers or flight crew traveled on commercial aircraft while infectious with TB.

MMWR: Case Definitions for Infectious Conditions Under Public Health Surveillance

This report provides updated uniform criteria for use by public health professionals when reporting the nationally notifiable infectious diseases listed in Part One of this report. A revision date is included for case definitions that have been revised. The case definitions for some infectious conditions not designated as nationally notifiable are included in Part Two of this report.

MMWR: Nucleic Acid Amplification Tests for Tuberculosis

This report summarizes potential uses of nucleic acid amplification (NAA) tests such as the Amplified Mycobacterium Tuberculosis Direct Test (MTD) for TB diagnosis and provides interim guidelines for the use of such tests. The report lists the current NAA tests, their FDA approved uses, their non-approved indications also known as off-label uses, limitations, and cautions.

State TB Control Offices

This fact sheet lists the TB control offices in all 50 states plus eight US territories (American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Puerto Rico, Republic of Marshall Islands, Republic of Palau, and Virgin Islands).

Lantos-Hyde US Government Tuberculosis Strategy

In response to the urgent need to control the spread of TB, the U.S. Congress passed the Reauthorization Act supporting a substantial increase in USG funding for TB treatment and control over a five-year period. The Reauthorization Act requests the development of a USG Global Tuberculosis Strategy.